WillItSurvive
Medical technology and health companies · United States

Phreesia

phreesia.com ↗

Phreesia runs patient intake, payments, and check in software for healthcare providers.

Protection under test
Assessed 22 July 2026 · Evidence as of 22 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 22 July 2026 · Checkable from late August to September 2026 · Every call on the record Checkpoint: Q2 FY2027 earnings, watch subscription revenue trend and pharma Network Solutions stabilization
The call

Phreesia is profitable and wired deep into thousands of clinics, but a pharma ad slowdown and a shrinking subscription line are testing whether its integrations can outrun both AI intake tools and its own investors' patience.

Phreesia helps hospitals and doctor's offices collect patient information, process payments, and run ads for pharmaceuticals. It is hard to copy quickly because it is plugged into over 4,500 hospitals' existing computer systems and handles $1.79 billion in payments every quarter, which competitors like Epic (a bigger EHR company) and simple AI chatbots cannot easily replace overnight. The company just cut its sales forecast by $35 million in March 2026 due to pharmaceutical advertisers spending less, laid off about 30 percent of staff, and faces a lawsuit, which means the stock crashed and profits are shaky right now, even though the core business appears solid. The one thing that could change everything is whether the pharma advertising slowdown bounces back quickly or turns out to be a permanent shift in how drug makers spend money.

Why
01
AI pressure: Perspective AI and other conversational-AI intake tools. AI intake bots could commoditize the check in form, but Phreesia is folding its own VoiceAI (Chloe) into the same workflow instead of getting replaced by it. Could AI do the core job? Only partly.
02
Bigger players: Epic Systems (MyChart). Epic pushes MyChart into more clinics, but it only works inside Epic's own EHR, leaving multi-EHR and independent practices to Phreesia. Could a giant copy it? No, they are blocked.
03
What protects it. Deep integrations into 4,500+ provider systems, $1.79B in quarterly payments flow, and 180M patient visits feeding a pharma ad network no point-solution can replicate fast.
What would change this call
Subscription and related services revenue trend in Q2-Q3 FY2027 earnings (Aug-Sept 2026). Shows whether core product demand is stabilizing or eroding further.
Pharma Network Solutions bookings/stabilization reported in upcoming quarters. Clarifies if ad softness was cyclical or a structural decline.
Epic MyChart or athenahealth announcing bundled intake+payments features for independent practices. Would show incumbents encroaching on Phreesia's integration moat.
Key numbers
  • Q1 FY27 revenue $130.9M, up 13% YoY (2026-04-30)
  • Stock fell 26% after FY27 guidance cut of $35-39M (2026-03-30)
  • Subscription revenue declined ~3% YoY to $52.72M (2026-04-30)
Named risks
  • Securities class action alleging concealed pharma-spending weakness, filed 2026-05 covering period through March 2026. Severity: high
  • Pharma manufacturer ad spending softness driving FY2027 guidance cut of $35-39M announced 2026-03-30. Severity: high
  • Core subscription revenue declined ~3% YoY to $52.72M in Q1 FY2027, signaling core-product softness. Severity: medium
  • Headcount down 14% YoY to 1,789 as of Jan 2026 with active restructuring, execution risk on savings. Severity: medium
  • Conversational-AI intake entrants like Perspective AI could commoditize Phreesia's form-based check-in workflow. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Epic Systems (MyChart)contestingNative EHR-bundled intake gives Epic structural advantage within its own hospital installed base, per Feb 2026 buyer's guide
athenahealthcontestingEHR-bundled intake alternative listed as adjacent competitor to Phreesia, June 2026 analysis
Perspective AIgaining onRanked above form-based platforms like Phreesia on clinical-context capture in June 2026 comparison
Luma HealthcontestingNamed alongside Phreesia in dedicated check-in/registration platform lane, June 2026
Questions people ask
Is Phreesia profitable in 2026?
Yes. Phreesia posted net income of $3M in Q1 FY2027 (ended April 30, 2026), its third consecutive profitable quarter, with adjusted EBITDA of $30.5M (~23% margin). FY2026 was its first full year of positive GAAP net income and record free cash flow, though FY2027 revenue guidance was cut sharply in March 2026.
Why did Phreesia stock crash in 2026?
Phreesia shares fell 26% on March 30, 2026 after management cut FY2027 revenue guidance by $35-39M, from $545-559M to $510-520M, citing weaker pharmaceutical-manufacturer ad spending on vaccines, GLP-1s and public-health marketing in its Network Solutions segment.
Is Phreesia laying off employees?
Yes. Headcount fell to 1,789 as of January 31, 2026, down 14.07% (-293) from 2,082 a year earlier, and Revelio Labs data shows a peak of ~2,695 in 2024 before contracting. In May 2026 Phreesia announced a formal restructuring plan to cut operating expenses.
Could AI replace Phreesia's patient intake product?
Partly at risk. Third-party analysis flags Phreesia's form-based intake as vulnerable to conversational-AI entrants like Perspective AI that capture clinical context better. But Phreesia's EHR integrations, payments infrastructure, and 180M+ annual patient visits (2025) are harder for AI point-solutions to replicate, and Phreesia itself launched VoiceAI in September 2025.
Who is Phreesia's biggest competitor?
Epic Systems, via its MyChart patient portal, is the most structurally adjacent incumbent threat given Epic's dominant U.S. hospital EHR footprint and native intake bundling. Other named competitors include athenahealth, Oracle Health, Luma Health, and AI-native entrant Perspective AI, per a June 2026 third-party comparison.
Is Phreesia being sued?
Yes. Multiple law firms including Kirby McInerney, Pomerantz, Rosen, and Levi & Korsinsky filed or solicited a securities class action covering May 8, 2025 to March 30, 2026, alleging Phreesia concealed weakening pharma-spending visibility before its March 2026 guidance cut; lead plaintiff deadline was July 13, 2026.
Timeline
  • 2026-07-22Market cap roughly $655M, stock trading $10.19-$10.29, near 52-week lows
  • 2026-07-21MediFind, Phreesia-owned, launched Chloe AI chatbot for provider search and booking
  • 2026-05-27Q1 FY2027 results: revenue $130.9M up 13% YoY, net income $3M
  • 2026-05Phreesia announced formal restructuring plan to cut operating expenses
  • 2026-03-30FY2027 guidance cut $35-39M; stock fell 26% on pharma ad softness
  • 2025-11-12Completed ~$160M acquisition of AccessOne from Frontier Growth
  • 2025-09-02Launched Phreesia VoiceAI conversational-AI phone agent
  • 2025-05-08Start date of securities class action period against Phreesia
Revision history
22 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
23andMeAngelalign TechnologySharecare
More in Medical technology and health companies →
Sources